Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.
Elisa Fontana(Sarah Cannon Research Institute), Takeharu Yamanaka(National Cancer Center Hospital East), Ioannis Boukovinas, Irit Ben‐Aharon(Technion – Israel Institute of Technology), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Jeffrey A. Meyerhardt(CancerCare), Andrea Harkin(Queen's University Belfast), Markus Moehler(Johannes Gutenberg University Mainz), Qian Shi(Mayo Clinic), Florian Lordick(Leipzig University), Axel Grothey(Mayo Clinic), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Takayuki Yoshino(University of Tsukuba), Anthony F. Shields(Wayne State University), Thierry André(Inserm), Ioannis Souglakos(University of Crete), Roberto Labianca(Ospedale Papa Giovanni XXIII), Alberto F. Sobrero(Ospedale Policlinico San Martino), Elizabeth Catherine Smyth(Churchill Hospital), Jeffrey P. Meyers(Mayo Clinic in Florida)
Cited by 2
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k